Regeneron bets $125M upfront on Parabilis Helicons: antibody-peptide conjugates step out of the shadows

What Was Announced

On Monday, May 18, 2026, the Cambridge, Massachusetts biotech Parabilis Medicines announced a strategic research collaboration with Regeneron Pharmaceuticals to develop a new class of medicines the company calls Antibody-Helicon Conjugates. Regeneron is paying $50 million upfront and committing to a $75 million equity investment in Parabilis's next financing. If the work goes well across the five initial targets covered by the deal, Parabilis is eligible for up to roughly $2.2 billion in development, regulatory, and commercial milestone payments, plus tiered royalties up to the low double digits on net sales. Regeneron takes responsibility for moving any resulting medicines through development, manufacturing, and worldwide commercialization. Parabilis keeps the platform.

The deal is notable for two reasons that have nothing to do with the headline numbers. First, it places a major bet on a peptide modality that, until recently, lived almost entirely in academic structural-biology labs — stabilized alpha-helical peptides engineered to slip into cells and engage protein surfaces that traditional drug discovery has spent thirty years calling "undruggable." Second, it pairs that peptide with an antibody, the way an antibody-drug conjugate pairs a small molecule with an antibody — except now the payload is itself a precision targeting peptide rather than a generic cytotoxic.

That combination is the part of the announcement worth reading carefully. Antibody-drug conjugates have been a major commercial story for a decade; antibody-peptide conjugates have not. If this deal works, the modality changes.

Key Facts

• Announced: Monday, May 18, 2026. Parabilis press release.
• Parties: Parabilis Medicines (Cambridge, MA, clinical-stage biopharmaceutical) and Regeneron Pharmaceuticals.
• Focus: Antibody-Helicon™ Conjugates (AHCs) — a novel class pairing Regeneron antibodies with Parabilis Helicon peptide payloads against historically undruggable intracellular targets.
• Initial targets: Five, with options for more under additional payments.
• Upfront: $50 million cash to Parabilis.
• Equity: $75 million Regeneron equity investment in Parabilis's next financing round.
• Milestones: Up to ~$2.2 billion across the five initial targets, plus tiered royalties up to low double digits.
• Helicons defined: Stabilized, cell-penetrant alpha-helical peptides able to engage flat intracellular protein surfaces poorly suited to small-molecule binders.
• Parabilis lead asset: Zolucatetide (formerly FOG-001), the first direct inhibitor of the β-catenin/TCF interaction. Indications under study include colorectal cancer, desmoid tumors, prostate cancer, and other Wnt/β-catenin-driven tumors.
• Other named programs: Investigational degraders of ERG and AR^ON for prostate cancer.
• Executive quoted: Mathai Mammen, M.D., Ph.D., Chairman, CEO and President of Parabilis Medicines.

What a Helicon Actually Is

Most peptide drugs in clinical use are signaling molecules — insulin, GLP-1 analogues, octreotide, oxytocin. They work outside the cell, on receptors at the surface. They are easy to give as injections, easy to manufacture, and well-defined chemically. They are also, by design, restricted to the extracellular face of the cell. Everything happening inside the cell, including most cancer-driving protein-protein interactions, has historically belonged to small molecules or, in a few cases, antibodies engineered to enter cells through complicated tricks.

Helicons sit in a different category. They are short peptides, on the order of fifteen to twenty amino acids, locked into an alpha-helical shape by chemical bridges or backbone modifications. The stabilization matters. An ordinary peptide of that length is a floppy chain in solution — entropically expensive to assemble into an active shape, and chewed up by proteases within minutes of entering the bloodstream. A stabilized helix holds its three-dimensional structure under physiological conditions, presents a defined face to its protein target, and resists enzymatic degradation long enough to do useful work. Combine that with chemical features that promote crossing the cell membrane — cell-penetrance, in the field's shorthand — and you get a molecule that behaves more like a small-molecule drug than like a classical peptide hormone.

The interesting target class is intracellular protein-protein interactions with flat binding surfaces. Transcription factor pairs. Oncogene-effector handshakes. Tumor-suppressor disabling interactions. Small molecules struggle with these because there's no deep pocket to fill. Antibodies struggle with them because they live on the wrong side of the membrane. A stabilized helix can land on a flat surface, occupy several thousand square angstroms of binding interface at once, and do so from inside the cell. That capability is the whole reason this company exists.

The Deal, Read Closely

The cash structure is straightforward enough. Fifty million dollars hits Parabilis's balance sheet at signing. Seventy-five million more is committed to the next equity round, which gives Regeneron a meaningful stake in a private company without forcing Parabilis to take that capital today. The milestone schedule, up to $2.2 billion across five targets, works out to an average of around $440 million per target if every single milestone hits, which essentially never happens; in practice, deals like this pay out a fraction of the headline number based on how many programs actually reach approval and how successful they are commercially.

The interesting structural choice is who does what. Parabilis runs discovery alongside Regeneron, then Regeneron takes the resulting molecules through development, manufacturing, and worldwide commercialization. That split is common in deals between a platform company and a Big Biotech partner, but it also tells you what each side is bringing. Parabilis owns the Helicon chemistry — the design rules, the stabilization strategies, the screening pipeline, the manufacturing know-how for stabilized helical peptides at therapeutic scale. Regeneron owns the antibody library, the conjugation chemistry, and, more importantly for commercial economics, the global development and sales infrastructure. The two companies are stitching their respective capabilities into one molecular class.

Five initial targets matters too. It signals this is a platform deal rather than a single-asset license. The expectation is that the joint team will discover five new medicines, not one. Whether all five reach the clinic depends on biology that hasn't been done yet. But the structural intent is clear: the parties believe AHCs are a modality, not a one-off.

How an Antibody-Helicon Conjugate Is Supposed to Work

An antibody-drug conjugate has three parts: an antibody that binds a tumor-specific surface protein, a chemical linker, and a cytotoxic payload. The antibody finds the cancer cell. The cell internalizes the whole construct. Once inside, the linker is cleaved, and the cytotoxic payload kills the cell from within. ADCs work commercially because they concentrate a toxic small molecule at the tumor while sparing healthy tissue. The major approved drugs in the class — T-DXd, Enhertu, Padcev, Trodelvy — have changed standard-of-care in several solid tumors.

An antibody-Helicon conjugate inherits the same architecture but swaps the payload. Instead of a cytotoxic small molecule, the antibody is delivering a stabilized alpha-helical peptide engineered to bind a specific intracellular protein. Once internalized, the Helicon is liberated from the antibody and engages its target inside the cell. The cell isn't killed by general cytotoxicity. It is rewired by specific blockade of a disease-driving interaction.

The therapeutic logic, if it works, is appealing. ADCs have to balance potency against off-target toxicity; the cytotoxic payload kills any cell it gets into. An AHC with a target-selective Helicon payload should be specific at two levels: the antibody picks the cell, and the Helicon picks the intracellular protein. The therapeutic window potentially widens. The off-target burden potentially narrows.

That logic is theoretical until the molecules are in patients. The conjugation chemistry has to be stable in circulation, cleavable inside cells. The Helicon has to survive endosomal escape and reach its target. The biology has to be right; some intracellular proteins won't tolerate inhibition without compensatory pathways kicking in. Each of those is an open question. The Parabilis-Regeneron deal is a bet that those questions are answerable within a reasonable program timeline.

Zolucatetide and the Track Record So Far

The reason Regeneron wrote the check is not the AHC concept in the abstract. It is the data Parabilis has already generated with its lead asset, zolucatetide, formerly known as FOG-001. Zolucatetide is the first direct inhibitor of the interaction between β-catenin and the TCF family of transcription factors. β-catenin is the central effector of the Wnt signaling pathway, mutated or dysregulated in a large fraction of colorectal cancers, in desmoid tumors, in some prostate cancers, and in several other solid malignancies. The β-catenin/TCF interaction has been a notorious cancer target for thirty years. Small molecules have tried. Antibodies have tried. The interaction surface is flat, broad, and chemically unforgiving. Nobody has gotten a direct inhibitor of it into clinical use.

Parabilis got there with a Helicon. Zolucatetide is in clinical development, and the lead-asset story underwrites the rest of the platform's credibility — the company has shown it can take an undruggable target, design a stabilized helix that engages it, and move that molecule into patients. The Regeneron deal extends that capability into an antibody-conjugate format and applies it to five new targets.

Two other named programs in the pipeline target prostate cancer: a Helicon degrader of the ETS transcription factor ERG, and a degrader of an active form of the androgen receptor designated AR^ON. Both are classical undruggable targets. The fact that the company is pursuing them with Helicons — not antibodies, not small molecules — reinforces what the platform is for.

Where Helicons Fit in the Peptide Therapeutics Landscape

The therapeutic peptide field has been organized for decades around extracellular signaling. GLP-1 receptor agonists for metabolic disease. Somatostatin analogues for neuroendocrine tumors. PTH analogues for osteoporosis. Oxytocin and vasopressin analogues for obstetric and renal indications. The market is large, growing, and increasingly dominated by GLP-1 pharmacology, but the molecules all work outside the cell.

Several newer companies have been working to break that pattern. Bicyclic peptide platforms from Bicycle Therapeutics target extracellular and tumor-microenvironment proteins. Stapled-peptide companies built around the Verdine and Walensky chemistry have pursued p53/MDM2 and other intracellular targets, with mixed clinical outcomes. Cyclic peptide discovery using mRNA display and the RaPID platform has generated multiple clinical candidates, including the macrocyclic peptide HL4 insulin-receptor agonist highlighted in Suga's recent paper. Each of these approaches solves part of the intracellular access problem in a different way.

Helicons claim a particular niche: stabilized alpha helices designed specifically for flat protein-protein interaction surfaces, packaged either as standalone therapeutics or as antibody payloads. The standalone version is what zolucatetide is. The AHC version is what this deal is about. If both formats work, Parabilis has positioned a single chemistry platform to feed both the standalone peptide drug market and the antibody-conjugate market — two large adjacent commercial spaces with very different go-to-market mechanics.

For the broader peptide field, the Regeneron deal is a signal. BLMP6, the UTHealth peptide identified by in vivo phage display and conjugated to MMAE, was a recent example of the peptide-drug-conjugate idea applied to an extracellular tumor matrix target. The TransCODE consortium's recent Nature paper on peptideins — 1,785 newly catalogued microproteins — expanded the discovery landscape on the cellular biology side. AHCs as a modality say something different again: peptide payloads as a complement, and perhaps a successor in some indications, to the cytotoxic-payload ADC story that has dominated solid-tumor drug development since the late 2010s.

Why Regeneron Cares

Regeneron is one of the two or three companies in the world most identified with antibody therapeutics. Eylea. Dupixent. The COVID antibody cocktail. The company's commercial position is anchored in antibody discovery, antibody engineering, and antibody manufacturing. Antibody-drug conjugates have been a missing piece of the portfolio compared to peers, and the broader ADC space has consolidated around a handful of dominant payload platforms.

An AHC platform gives Regeneron a differentiated payload story without competing head-on with the cytotoxic-ADC majors. Helicons are not the same chemistry as the topoisomerase-inhibitor or microtubule-disruptor payloads that dominate approved ADCs. They are not made the same way. They don't compete for the same intellectual property landscape. They open a target class — intracellular protein-protein interactions — that cytotoxic ADCs cannot address by design.

If the platform works, Regeneron acquires both a differentiated modality and an entry point into oncology indications where current ADC chemistry has hit its limits. If it doesn't, the cost is $125 million in upfront and equity commitments, against a portfolio of antibody assets and a balance sheet that can absorb the bet without distress. The risk-reward favors writing the check.

What to Watch Over the Next 12-24 Months

Several markers will tell us whether AHCs become a real modality.

First: zolucatetide clinical data. The lead Helicon asset is in clinical trials. Efficacy and safety readouts from those studies will set the floor for how seriously the field takes the platform. If a standalone Helicon hits its β-catenin/TCF target in patients with the predicted pharmacology, the AHC concept becomes more credible. If it doesn't, the AHC value proposition gets harder to underwrite.

Second: target selection for the five initial AHC programs. The press release does not name them. The first program announcements, whenever they come, will signal which intracellular targets the joint team thinks are tractable. Watch for indications where antibody specificity and intracellular target specificity stack productively — tumor types with both a clean surface marker and a high-value intracellular driver.

Third: any pre-clinical disclosure on AHC pharmacokinetics and endosomal escape. The hardest engineering problem with antibody-peptide conjugates is keeping the antibody-Helicon construct intact in circulation, then liberating the Helicon inside the cell in a form that can reach its intracellular target. Public data on this from either Parabilis or Regeneron will tell us whether the chemistry is solved or still in development.

Fourth: follow-on deals. If AHCs work, other antibody-dominant companies — Roche, AstraZeneca, Daiichi Sankyo — will look for their own peptide-payload partnerships. The first competitive AHC deal will mark the modality as mainstream.

What This Means for Different Audiences

For oncology clinicians: nothing in clinical practice changes today. Watch for AHC-format trial postings on ClinicalTrials.gov over the next twelve months; the deal sets up a pipeline that will start enrolling patients in the second half of the decade.

For peptide chemists: stabilized alpha-helical chemistry — staples, stitches, hydrogen-bond surrogates, helix-promoting backbone modifications — just got a $125 million validation as an antibody-conjugate payload platform. Expect academic and biotech interest in helix-stabilization chemistry to spike.

For investors: the deal sets a comparable for stabilized-peptide platform deals. $50 million upfront plus $75 million equity for a five-target collaboration with a clinical-stage lead is a useful reference number for the next platform deal in the category.

For patients: not yet a development that affects available treatment options. The therapeutic horizon for AHCs from this collaboration is several years out at minimum. The interesting near-term clinical question is whether zolucatetide produces meaningful responses in β-catenin-driven tumors, which would validate the underlying chemistry independently of the AHC format.

Related Coverage

• BLMP6 peptide — UTHealth's phage-display peptide-drug conjugate against fibulin-4-marked metastatic breast cancer. Same conjugate logic, extracellular target.
• Peptideins: Nature's new molecular category — the 1,785 newly catalogued microproteins from the TransCODE consortium that expand the peptide discovery landscape.
• HL4 macrocyclic insulin-receptor agonist — Suga lab cyclic peptide discovery as an adjacent intracellular-access strategy.
• Peptide therapeutics — broader category context.

Frequently Asked Questions

What is a Helicon peptide?

A Helicon is Parabilis Medicines' proprietary class of stabilized, cell-penetrant alpha-helical peptides. The peptides are locked into a defined helical shape by chemical modifications, engineered to cross cell membranes, and designed to bind flat intracellular protein-protein interaction surfaces that conventional small molecules and antibodies can't engage. Helicons are typically fifteen to twenty amino acids long.

What is an Antibody-Helicon Conjugate?

An Antibody-Helicon Conjugate, or AHC, is a hybrid medicine that links an antibody to a Helicon peptide payload via a chemical linker. The architecture mirrors an antibody-drug conjugate, but the payload is a target-selective stabilized peptide rather than a cytotoxic small molecule. The antibody guides the construct to a specific cell type; once internalized, the Helicon engages a specific intracellular protein. The aim is precision targeting at two levels — cell-type selectivity through the antibody, target selectivity through the Helicon.

What did Regeneron pay for the deal?

Regeneron is paying Parabilis $50 million upfront, committing $75 million in equity in Parabilis's next financing round, and is on the hook for up to roughly $2.2 billion in milestone payments across five initial targets if the programs hit their development, regulatory, and commercial markers. Parabilis is also eligible for tiered royalties up to the low double digits on net sales of approved products.

What is zolucatetide?

Zolucatetide, previously called FOG-001, is Parabilis's lead clinical-stage Helicon. It is the first known direct inhibitor of the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors — a long-considered undruggable cancer target. Parabilis is developing zolucatetide in colorectal cancer, desmoid tumors, prostate cancer, and other Wnt/β-catenin-driven tumors.

How does this compare to antibody-drug conjugates already on the market?

Approved antibody-drug conjugates like Enhertu, Trodelvy, and Padcev pair antibodies with cytotoxic small-molecule payloads that kill any cell they enter. AHCs pair antibodies with Helicon peptide payloads that selectively modulate a specific intracellular protein. The expected difference is in the off-target profile: cytotoxic payloads damage any cell they reach; target-selective Helicons should only act when their specific intracellular protein is present. Whether that difference plays out in patients is the open clinical question.

Is this a drug that patients can take now?

No. The AHC programs covered by this deal are in early discovery. No AHC has been tested in humans yet. The lead standalone Helicon, zolucatetide, is in clinical trials, but that is a separate molecule from the AHC programs that the Regeneron partnership will pursue. Any AHC reaching the clinic from this collaboration is several years away.

How is a Helicon different from a stapled peptide?

Stapled peptides are alpha-helical peptides stabilized by a hydrocarbon "staple" introduced between two specific residues, a chemistry pioneered in the Verdine and Walensky labs. Helicons, as Parabilis describes them, are a broader category of stabilized, cell-penetrant alpha-helical peptides; the company has not publicly disclosed the specific chemistries used for stabilization. In practice, both approaches share the same therapeutic ambition — intracellular access for flat protein-protein interaction surfaces — and the distinction is largely about platform-specific chemistry rather than mechanism of action.

Sources

• Parabilis Medicines. "Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas." Press release, May 18, 2026. parabilismed.com.
• Parabilis Medicines. Company overview and platform description. parabilismed.com.
• BioPharma Dive. "Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug." May 18, 2026 (industry brief covering the Parabilis-Regeneron deal). biopharmadive.com.
• Regeneron Pharmaceuticals. Corporate pipeline and platform overview. regeneron.com.
• ClinicalTrials.gov. Zolucatetide / FOG-001 clinical program entries. clinicaltrials.gov.

This is a news summary of a corporate partnership announcement and pipeline disclosure. No Helicon or AHC product is FDA-approved. Nothing in this article is medical advice or investment advice. Trial enrollment information should be obtained from ClinicalTrials.gov or the sponsoring company.